clinical trial · NCT03691714
Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
University of Cincinnati·phase2·completed·n = 35
Recurrent Head and Neck CancerHead and Neck CancerHead and Neck NeoplasmsMetastatic CancerDurvalumabCetuximab
brief summary
The purpose of this research study is to test the combination of the anti-cancer drugs durvalumab, the study drug, and cetuximab as a treatment for metastatic or recurrent head and neck cancer. Participants will receive both durvalumab and cetuximab.
started
Oct 23, 2018
primary completion
Dec 1, 2024
completion
Dec 1, 2024
last updated
Sep 2, 2026
detailed description
This research study is designed to see if the study drug, durvalumab, will work better with cetuximab than either medicine alone along with the evaluation of side effects of the drug combination.
official title
An Open-label, Phase II Study of Durvalumab (MEDI4736) in Combination With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol